AbCellera Biologics Inc.
ABCL
$4.24
-$0.23-5.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 23.12M | 28.83M | 32.96M | 33.06M | 35.79M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 23.12M | 28.83M | 32.96M | 33.06M | 35.79M |
| Cost of Revenue | 170.47M | 167.26M | 169.81M | 166.75M | 162.30M |
| Gross Profit | -147.35M | -138.43M | -136.84M | -133.70M | -126.51M |
| SG&A Expenses | 83.84M | 85.49M | 85.40M | 80.96M | 76.99M |
| Depreciation & Amortization | 59.34M | 58.85M | 85.82M | 54.64M | 23.73M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 313.65M | 311.60M | 341.03M | 302.35M | 263.01M |
| Operating Income | -290.53M | -282.77M | -308.06M | -269.29M | -227.23M |
| Income Before Tax | -210.63M | -200.40M | -202.17M | -178.81M | -168.63M |
| Income Tax Expenses | -42.76M | -37.54M | -26.37M | -25.51M | -21.73M |
| Earnings from Continuing Operations | -167.87 | -162.86 | -175.80 | -153.30 | -146.90 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -167.87M | -162.86M | -175.80M | -153.30M | -146.90M |
| EBIT | -290.53M | -282.77M | -308.06M | -269.29M | -227.23M |
| EBITDA | -197.05M | -189.77M | -222.24M | -214.65M | -203.50M |
| EPS Basic | -0.57 | -0.55 | -0.60 | -0.53 | -0.51 |
| Normalized Basic EPS | -0.44 | -0.42 | -0.48 | -0.39 | -0.38 |
| EPS Diluted | -0.57 | -0.56 | -0.61 | -0.54 | -0.52 |
| Normalized Diluted EPS | -0.44 | -0.42 | -0.48 | -0.39 | -0.38 |
| Average Basic Shares Outstanding | 1.18B | 1.18B | 1.17B | 1.17B | 1.16B |
| Average Diluted Shares Outstanding | 1.18B | 1.18B | 1.17B | 1.17B | 1.16B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |